These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Indole-3-Carbonitriles as DYRK1A Inhibitors by Fragment-Based Drug Design. Meine R; Becker W; Falke H; Preu L; Loaëc N; Meijer L; Kunick C Molecules; 2018 Jan; 23(2):. PubMed ID: 29364148 [TBL] [Abstract][Full Text] [Related]
3. 10-iodo-11H-indolo[3,2-c]quinoline-6-carboxylic acids are selective inhibitors of DYRK1A. Falke H; Chaikuad A; Becker A; Loaëc N; Lozach O; Abu Jhaisha S; Becker W; Jones PG; Preu L; Baumann K; Knapp S; Meijer L; Kunick C J Med Chem; 2015 Apr; 58(7):3131-43. PubMed ID: 25730262 [TBL] [Abstract][Full Text] [Related]
4. Synthesis of new pyridazino[4,5-b]indol-4-ones and pyridazin-3(2H)-one analogs as DYRK1A inhibitors. Bruel A; Bénéteau R; Chabanne M; Lozach O; Le Guevel R; Ravache M; Bénédetti H; Meijer L; Logé C; Robert JM Bioorg Med Chem Lett; 2014 Nov; 24(21):5037-40. PubMed ID: 25248682 [TBL] [Abstract][Full Text] [Related]
5. Novel and Potential Small Molecule Scaffolds as DYRK1A Inhibitors by Integrated Molecular Docking-Based Virtual Screening and Dynamics Simulation Study. Shahroz MM; Sharma HK; Altamimi ASA; Alamri MA; Ali A; Ali A; Alqahtani S; Altharawi A; Alabbas AB; Alossaimi MA; Riadi Y; Firoz A; Afzal O Molecules; 2022 Feb; 27(4):. PubMed ID: 35208955 [TBL] [Abstract][Full Text] [Related]
6. Small Molecule Inhibitors of DYRK1A Identified by Computational and Experimental Approaches. Yoon HR; Balupuri A; Choi KE; Kang NS Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32957634 [TBL] [Abstract][Full Text] [Related]
7. Probing the ATP-Binding Pocket of Protein Kinase DYRK1A with Benzothiazole Fragment Molecules. Rothweiler U; Stensen W; Brandsdal BO; Isaksson J; Leeson FA; Engh RA; Svendsen JS J Med Chem; 2016 Nov; 59(21):9814-9824. PubMed ID: 27736065 [TBL] [Abstract][Full Text] [Related]
8. New pyrido[3,4-g]quinazoline derivatives as CLK1 and DYRK1A inhibitors: synthesis, biological evaluation and binding mode analysis. Tazarki H; Zeinyeh W; Esvan YJ; Knapp S; Chatterjee D; Schröder M; Joerger AC; Khiari J; Josselin B; Baratte B; Bach S; Ruchaud S; Anizon F; Giraud F; Moreau P Eur J Med Chem; 2019 Mar; 166():304-317. PubMed ID: 30731399 [TBL] [Abstract][Full Text] [Related]
9. Novel Scaffolds for Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase (DYRK1A) Inhibitors. Czarna A; Wang J; Zelencova D; Liu Y; Deng X; Choi HG; Zhang T; Zhou W; Chang JW; Kildalsen H; Seternes OM; Gray NS; Engh RA; Rothweiler U J Med Chem; 2018 Sep; 61(17):7560-7572. PubMed ID: 30095246 [TBL] [Abstract][Full Text] [Related]
10. Insights into mechanism of pyrido[2,3-d]pyrimidines as DYRK1A inhibitors based on molecular dynamic simulations. Li JJ; Tian YL; Zhai HL; Lv M; Zhang XY Proteins; 2016 Aug; 84(8):1108-23. PubMed ID: 27119584 [TBL] [Abstract][Full Text] [Related]
12. Synthesis of chromeno[3,4-b]indoles as Lamellarin D analogues: a novel DYRK1A inhibitor class. Neagoie C; Vedrenne E; Buron F; Mérour JY; Rosca S; Bourg S; Lozach O; Meijer L; Baldeyrou B; Lansiaux A; Routier S Eur J Med Chem; 2012 Mar; 49():379-96. PubMed ID: 22305342 [TBL] [Abstract][Full Text] [Related]
13. Development of novel amide-derivatized 2,4-bispyridyl thiophenes as highly potent and selective Dyrk1A inhibitors. Part II: Identification of the cyclopropylamide moiety as a key modification. Darwish SS; Abdel-Halim M; ElHady AK; Salah M; Abadi AH; Becker W; Engel M Eur J Med Chem; 2018 Oct; 158():270-285. PubMed ID: 30223116 [TBL] [Abstract][Full Text] [Related]
15. Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic β-cell proliferation activity. Kumar K; Man-Un Ung P; Wang P; Wang H; Li H; Andrews MK; Stewart AF; Schlessinger A; DeVita RJ Eur J Med Chem; 2018 Sep; 157():1005-1016. PubMed ID: 30170319 [TBL] [Abstract][Full Text] [Related]
16. Pharmacophore and 3D-QSAR characterization of 6-arylquinazolin-4-amines as Cdc2-like kinase 4 (Clk4) and dual specificity tyrosine-phosphorylation-regulated kinase 1A (Dyrk1A) inhibitors. Pan Y; Wang Y; Bryant SH J Chem Inf Model; 2013 Apr; 53(4):938-47. PubMed ID: 23496085 [TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of new 5-benzylated 4-oxo-3,4-dihydro-5H-pyridazino[4,5-b]indoles as PI3Kα inhibitors. Bruel A; Logé C; Tauzia ML; Ravache M; Le Guevel R; Guillouzo C; Lohier JF; Oliveira Santos JS; Lozach O; Meijer L; Ruchaud S; Bénédetti H; Robert JM Eur J Med Chem; 2012 Nov; 57():225-33. PubMed ID: 23063566 [TBL] [Abstract][Full Text] [Related]
18. Computational & experimental evaluation of the structure/activity relationship of β-carbolines as DYRK1A inhibitors. Drung B; Scholz C; Barbosa VA; Nazari A; Sarragiotto MH; Schmidt B Bioorg Med Chem Lett; 2014 Oct; 24(20):4854-60. PubMed ID: 25240617 [TBL] [Abstract][Full Text] [Related]
19. Kororamides, Convolutamines, and Indole Derivatives as Possible Tau and Dual-Specificity Kinase Inhibitors for Alzheimer's Disease: A Computational Study. Llorach-Pares L; Nonell-Canals A; Avila C; Sanchez-Martinez M Mar Drugs; 2018 Oct; 16(10):. PubMed ID: 30332805 [TBL] [Abstract][Full Text] [Related]
20. Synthesis, Docking Study and Kinase Inhibitory Activity of a Number of New Substituted Pyrazolo[3,4-c]pyridines. Sklepari M; Lougiakis N; Papastathopoulos A; Pouli N; Marakos P; Myrianthopoulos V; Robert T; Bach S; Mikros E; Ruchaud S Chem Pharm Bull (Tokyo); 2017; 65(1):66-81. PubMed ID: 28049917 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]